Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

30 Sept 2013

Abstract excerpt

INTRODUCTION: Endemic in Latin America, Chagas disease is now becoming a serious global health problem, and yet has no financial viability for the pharmaceutical industry and remains incurable. In 2012, two antimycotic drugs inhibitors of fungal sterol 14α-demethylase (CYP51) - posaconazole and ravuconazole - entered clinical trials. Availability of the X-ray structure of the orthologous enzyme from the causative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to Parasites and Host Interactions
Share to Trypanosoma species research and implications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24079515
DOI: 10.1517/17460441.2013.845554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?PMID 24079515Read ↗

Phenotypic screening approaches for Chagas disease drug discovery.Semantic proximity Read ↗

Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.Semantic proximity Read ↗

Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol.Semantic proximity Read ↗

Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive YeastSemantic proximity Read ↗

Recent Developments in the Chemotherapy of Chagas DiseaseSemantic proximity Read ↗

Tinospora Cordifolia Bioactive Compounds as a Novel Sterol 14a- Demethylase (Cyp51) Inhibitor: an Insilico StudySemantic proximity Read ↗

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.Semantic proximity Read ↗

Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.Semantic proximity Read ↗

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' DiseaseSemantic proximity Read ↗

New antibacterials for the treatment of toxoplasmosis; a patent reviewSemantic proximity Read ↗

Identification of echinoderm metabolites as potential inhibitors targeting wild-type and mutant forms of Escherichia coli RNA polymerase (RpoB) for tuberculosis treatment.Semantic proximity Read ↗

DRUG DISCOVERY AND DEVELOPMENT FOR NEGLECTED TROPICAL DISEASESSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.